8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K


                             CURRENT REPORT Pursuant
                          to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

     Date of report (Date of earliest event reported):  October 12, 2004


                           Integrated BioPharma, Inc.
             (Exact Name of Registrant as Specified in Its Charter)

                                    Delaware
                 (State or Other Jurisdiction of Incorporation)

          000-28876                                   22-2407475
  (Commission File Number)                  (IRS Employer Identification No.)

                225 Long Avenue
          Hillside, New Jersey 07205
  (Address of Principal Executive Offices)              (Zip Code)

                                 (973) 926-0816
              (Registrant's Telephone Number, Including Area Code)


          (Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
         (17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
         CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
         Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
         Exchange Act (17 CFR 240.13e-4(c))




Item 7.01. Regulation FD Disclosure

         On October 12, 2004,  Integrated  BioPharma,  Inc., a Delaware
corporation (the "Company"),  announced the appointment of Dr. Geoffrey Schild
to the Science Advisory Board of InB Biotechnologies, Inc. (formerly NuCycle
Therapy, Inc.) its wholly owned biotech subsidiary.  The press release is
attached as an exhibit to this Report.


Item 9.01. Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.   Description
99.1          Press Release issued by Integrated BioPharma, Inc. on
              October 12, 2004.

                                       1




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                  INTEGRATED BIOPHARMA, INC.


Date:  October 12, 2004         By: /s/ Eric Friedman
                                  Eric Friedman
                                  Vice President and Chief Financial Officer

EX-99

Contact: Michael Mason (investors)          Eric Friedman, CFO
         Allen & Caron Inc                  Integrated BioPharma Inc
         212 691 8087                       888 319 6962
         michaelm@allencaron.com            e.friedman@chemintl.com

              INTEGRATED BIOPHARMA, INC. ANNOUNCES NEW APPOINTMENT
                        TO ITS SCIENTIFIC ADVISORY BOARD

HILLSIDE, NJ - Integrated BioPharma Inc. (AMEX:INB), announced the appointment
of Dr. Geoffrey Schild to the Science Advisory Board of InB Biotechnologies,
Inc. (formerly NuCycle Therapy, Inc.) its wholly owned biotech subsidiary. Dr.
Schild is the Professional Affairs Officer of the Society for General
Microbiology, the largest microbiological professional society in Europe with
over 5,000 members.

     Dr. Schild's career has been mainly in the field of virology, vaccinology
and public health. From 1985 through 2002, he was Director and Chief Executive
of the National Institute for Biological Standards and Control (NIBSC) and a
member of the National Biological Standards Board and its subcommittees.

     Dr. Schild has been the driving force in monitoring flu vaccine strains and
in setting standards for flu vaccine production on a global basis. Dr. Schild
has followed a scientific career in biological sciences with particular emphasis
on applied medical virology and research. His special scientific interests have
included influenza virology research and the standardization and control of
vaccines and other biological products.

     "We are pleased to have such an esteemed professional as Dr. Geoffrey
Schild join the Scientific Advisory Board," stated E. Gerald Kay, CEO of
Integrated BioPharma Inc. "Dr. Schild's scientific knowledge and regulatory
affairs experience will be a strong addition to our distinguished Board."

About Integrated BioPharma Inc (INB)

     INB serves the pharmaceutical, biotech and nutraceutical industries. INB's
biotech subsidiary, InB Biotechnologies, Inc., is developing human therapeutics
and preventive compounds using a transient gene expression system and transgenic
plant technology. INB's pharmaceutical subsidiary, Paxis Pharmaceuticals, Inc.,
develops and operates a state-of-the-art GMP facility for the production and
sale of paclitaxel and related drugs. INB's nutraceutical subsidiary, Manhattan
Drug, develops, manufactures and distributes more than 130 products worldwide.
Further information is available at www.iBioPharma.com.

     Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and the company's
ability to obtain new contracts and accurately estimate net revenues due to
variability in size, scope and duration of projects, and internal issues in the
sponsoring client. Further information on potential risk factors that could
affect the company's financial results can be found in the company's reports
filed with the Securities and Exchange Commission.